OSALMID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H11NO3
Molecular Weight	229.2313
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(NC(=O)C2=CC=CC=C2O)C=C1

InChI

InChIKey=LGCMKPRGGJRYGM-UHFFFAOYSA-N

InChI=1S/C13H11NO3/c15-10-7-5-9(6-8-10)14-13(17)11-3-1-2-4-12(11)16/h1-8,15-16H,(H,14,17)

HIDE SMILES / InChI

Molecular Formula	C13H11NO3
Molecular Weight	229.2313
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://ntrs.nasa.gov/archive/nasa/casi.ntrs.nasa.gov/19800013487.pdf
Curator's Comment: Description was created based on several sources, including http://eurekamag.com/research/025/967/025967995.php and http://lekarstwo.ru/en/preparati/oxaphenamidum.html

Osalmid (Oxaphenamide) is a choleretic drug. It is also recommended for use as a choleretic, principally in combination with antibiotics, in the convalescent stage of infectious hepatitis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Ribonucleoside-diphosphate reductase M2 chain 2 Target ID: CHEMBL1954 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26774458	Inhibitor 8504		8.23 µM [IC50]
HBV DNA replication 1 Target ID: HBV DNA replication Sources: http://www.ncbi.nlm.nih.gov/pubmed/26774458	Inhibitor 8504		11.1 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cholecystitis 12 Sources: http://www.ncbi.nlm.nih.gov/pubmed/14484267	Primary		Preclinical	Unknown Approved Use Unknown
Infectious hepatitis 2 Sources: http://eurekamag.com/research/025/967/025967995.php	Palliative		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein.	2016-03-01	26774458
[Selection of optimal conditions for analyzing oxaphenamide by the differential spectrophotometry method].	1972-01-01	5039877
[Effect of oxaphenamide on bile excretion and bile acid synthesis in experimental radiation sickness].	1972	5011512
[Comparative study of action of dehydrocholic acid and oxaphenamide on bile secretion and cholate formation].	1970-07-01	5525960
[Effect of dehydrocholic acid and oxaphenamide on the bile secretory function of the liver in adrenalectomized animals].	1968-03-01	5674676
[Choleretic properties of oxaphenamide].	1967-07-01	5598898

Patents

Sample Use Guides

In Vivo Use Guide

Tablets of 0.25 - 0.5 g three times a day before meals. The course of treatment, on average, 15 to 20 days

Route of Administration: Oral

In Vitro Use Guide

After treatment for 8d, the 50% effective concentrations of osalmid (EC50) for HBV DNA inhibition were 11.1 uM for culture supernatant and 16.5 uM for HepG2.2.15 cells, as determined by Q-PCR

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:29:15 GMT 2025` Edited by `admin` on `Mon Mar 31 18:29:15 GMT 2025`
Record UNII	89741L759Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OSALMID

Official Name

English

L-1718

Preferred Name

English

Osalmid [WHO-DD]

Common Name

English

osalmid [INN]

Common Name

English

OSALMID [MI]

Common Name

English

OSALMID [MART.]

Common Name

English

OSALMID [JAN]

Common Name

English

4'-HYDROXYSALICYLANILIDE

Systematic Name

English

NSC-93960

Code

English

Classification Tree Code System Code

EPA PESTICIDE CODE

217801